Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7803838 | ALLERGAN | Compositions comprising nebivolol |
Aug, 2026
(3 years from now) | |
US7838552 | ALLERGAN | Compositions comprising nebivolol |
Oct, 2027
(4 years from now) |
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
8
United States
5
European Union
3
Russia
3
China
2
Israel
2
Singapore
2
South Africa
2
Canada
2
Australia
2
Korea, Republic of
2
New Zealand
2
AP
1
Hong Kong
1
Japan
1
Austria
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic